GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BeyondSpring Inc.
BeyondSpring is a biopharmaceutical company developing oncology drugs. Its stock price reflects the binary risks of clinical trials. The chart is a story of high hopes and sharp declines following the publication of study data and FDA decisions.
Share prices of companies in the market segment - General oncology therapy
BeyondSpring is a biopharmaceutical company developing innovative oncology drugs, the main one of which, plinabulin, is designed to reduce chemotherapy-induced neutropenia. We have classified the company in the "General Oncology Therapy" segment. The chart below shows the overall dynamics of the maintenance therapy sector in oncology.
Broad Market Index - GURU.Markets
BeyondSpring is a biopharmaceutical company developing drugs for the treatment of oncology diseases, particularly those aimed at combating the side effects of chemotherapy. Its focus on maintenance therapy makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how BeyondSpring compares to it.
Change in the price of a company, segment, and market as a whole per day
BYSI - Daily change in the company's share price BeyondSpring Inc.
For BeyondSpring Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about clinical trials and regulatory decisions, and is an important metric for assessing risk.
Daily change in the price of a set of shares in a market segment - General oncology therapy
For BeyondSpring Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about clinical trials and regulatory decisions, and is an important metric for assessing risk.
Daily change in the price of a broad market stock, index - GURU.Markets
BeyondSpring Inc. is a biopharmaceutical company developing cancer treatments. Its future depends on the success of clinical trials and regulatory approval. The company's shares are in a state of anticipation of news, and their sharp fluctuations, full of both hope and risk, contribute to the dramatic and volatile market pulse, visible on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BeyondSpring Inc.
For BeyondSpring Inc., its year-over-year performance is a story of its struggle to secure approval for its drug to treat the side effects of chemotherapy. Its 12-month market cap is crucially dependent on the FDA's decisions. The regulator's rejection was a serious blow, and its valuation now reflects its belief that the company can overcome these challenges and grow its other assets.
Annual dynamics of market capitalization of the market segment - General oncology therapy
BeyondSpring Inc. is a late-stage biotech company developing cancer treatments. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this complex area of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BeyondSpring is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BeyondSpring Inc.
BeyondSpring is a late-stage biopharmaceutical company focused on oncology. Its monthly performance is extremely sensitive to regulatory decisions. FDA news regarding its lead drug, plinabulin, can cause significant price changes in a short period.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
BeyondSpring is a biopharmaceutical company whose lead drug is designed to reduce chemotherapy-induced neutropenia. The company's future depends on regulatory approval and successful commercialization. The oncology sector chart provides a general context for assessing potential demand for BeyondSpring's maintenance therapy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BeyondSpring Inc. is a biopharmaceutical company developing cancer treatments. Its shares, like many in the sector, are moving in anticipation of regulatory decisions and clinical trial data. Their monthly performance is almost completely disconnected from overall market sentiment, making the chart reflect scientific risks and hopes.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BeyondSpring Inc.
BeyondSpring, a late-stage biopharmaceutical company developing oncology drugs, exhibits high volatility. Weekly stock performance depends on news about regulatory decisions (such as the FDA) and clinical trial data, each of which is key.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
BeyondSpring Inc. develops innovative drugs for cancer treatment, including those designed to combat the side effects of chemotherapy. The chart helps separate its own news-driven dynamics from the overall fluctuations in the oncology sector, revealing its place within the industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BeyondSpring is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that BYSI's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
BYSI - Market capitalization of the company BeyondSpring Inc.
BeyondSpring's chart is a financial map of the battle against chemotherapy side effects. The company's market cap reflects the hopes for its drug, designed to prevent neutropenia. Its volatility reflects its complex regulatory path and the belief that its drug could become a new standard of maintenance therapy in oncology.
BYSI - Share of the company's market capitalization BeyondSpring Inc. within the market segment - General oncology therapy
BeyondSpring's market share in oncology is based on its lead drug, which aims to protect patients' immune systems during chemotherapy. Its market share reflects this drug's enormous potential to become a standard of care for preventing severe side effects.
Market capitalization of the market segment - General oncology therapy
BeyondSpring is an oncology company developing drugs to combat the side effects of chemotherapy. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect the importance of not only cancer treatment but also improving patients' quality of life.
Market capitalization of all companies included in a broad market index - GURU.Markets
BeyondSpring is a biopharmaceutical company developing drugs to treat cancer and mitigate the side effects of chemotherapy. Its market capitalization reflects the potential of its portfolio. The chart below shows the economic weight of companies working in the supportive care field.
Book value capitalization of the company, segment and market as a whole
BYSI - Book value capitalization of the company BeyondSpring Inc.
For BeyondSpring, an oncology company, book value is its capital. The chart below shows the financial resources needed to advance its lead drug through regulatory hurdles in the US and China. This is a story about the financial foundation for global commercialization.
BYSI - Share of the company's book capitalization BeyondSpring Inc. within the market segment - General oncology therapy
BeyondSpring is a late-stage biopharmaceutical company developing cancer treatments. Its core capital is intellectual property. Its physical asset allocation will be minimal, reflecting a focus on clinical trials rather than large manufacturing facilities.
Market segment balance sheet capitalization - General oncology therapy
BeyondSpring is a late-stage biotech company. Its value is created in labs, not factories. It's a "lightweight" model. The chart below shows how much the biopharmaceutical industry as a whole relies on physical assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
BeyondSpring's balance sheet represents capital focused on developing a drug that protects against neutropenia (a drop in white blood cell count), a common and dangerous side effect of chemotherapy. The balance sheet value chart shows the amount of resources devoted to improving the quality of life for cancer patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BeyondSpring Inc.
BeyondSpring is a biotech company developing oncology drugs. Its market capitalization reflects the valuation of its lead drug candidate. The chart shows extreme volatility associated with regulatory decisions (FDA), which can either create or destroy enormous value.
Market to book capitalization ratio in a market segment - General oncology therapy
BeyondSpring is a late-stage biopharmaceutical company developing oncology drugs. Its value is almost entirely dependent on the approval and success of its lead drug. The chart shows how its market valuation reflects the likelihood of this success, according to investors.
Market to book capitalization ratio for the market as a whole
BeyondSpring is a biopharmaceutical company developing cancer treatments. The chart shows how the market values the company after regulatory setbacks. Its market capitalization reflects both the potential of its remaining drugs in development and the high level of investor skepticism, creating a significant gap between hopes and reality.
Debts of the company, segment and market as a whole
BYSI - Company debts BeyondSpring Inc.
BeyondSpring is a late-stage biopharmaceutical company focused on oncology. Debt instruments at this stage can be critical for funding preparations for the commercial launch of its lead drug and additional research, as reflected in this chart.
Market segment debts - General oncology therapy
BeyondSpring is a late-stage biopharmaceutical company developing oncology drugs. Having a drug in late-stage trials requires significant capital to complete the trials and prepare for launch. The chart shows common financial metrics for the pharmaceutical sector, which can be used to assess how the company is funding this final and most expensive step to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BeyondSpring Inc.
BeyondSpring is a biopharmaceutical company whose lead drug is designed to protect against chemotherapy-induced neutropenia. Bringing a new drug to market is the final, but very costly, stage. This chart shows how the company finances its product's commercialization, allowing us to assess its financial risks at the threshold of revenue generation.
Market segment debt to market segment book capitalization - General oncology therapy
Developing drugs to treat the side effects of chemotherapy, like BeyondSpring's, aims to improve the quality of life for cancer patients. This chart shows how the biotech sector funds its R&D. It allows one to assess the company's financial model and its dependence on clinical trial success, relative to the broader pharmaceutical industry focused on cancer treatment.
Debt to book value of all companies in the market
BeyondSpring develops innovative cancer treatments. The path from idea to commercialization in oncology is long and requires significant investment. This chart allows investors to see how the company's debt load, taken on to support future breakthroughs, compares to the overall debt level in the market.
P/E of the company, segment and market as a whole
P/E - BeyondSpring Inc.
This chart shows the valuation of BeyondSpring, a late-stage biopharmaceutical company. The metric reflects investor expectations regarding the approval and commercial success of its lead drug, which is designed to combat the side effects of chemotherapy.
P/E of the market segment - General oncology therapy
This indicator represents the average valuation for the biotech sector in which BeyondSpring operates. It reflects the overall level of investor optimism regarding scientific breakthroughs in oncology. The chart provides a benchmark for understanding how the market evaluates BeyondSpring's developments relative to the broader industry.
P/E of the market as a whole
BeyondSpring is a biopharmaceutical company whose lead drug is designed to reduce chemotherapy-induced neutropenia. The company's success depends on the approval and commercialization of this product. This chart shows biotech sentiment. It helps understand how the market perceives this drug's potential to become a new standard in cancer supportive care and how this relates to overall trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BeyondSpring Inc.
BeyondSpring is a biopharmaceutical company developing drugs to treat cancer. Its lead candidate is designed to reduce chemotherapy-induced neutropenia. The company's future depends on regulatory approval and commercial success. This chart reflects investor expectations for its lead drug and the potential of other oncology developments in its pipeline.
%20P%2FE%20BeyondSpring%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BeyondSpring-Inc.&v=1772513436807 "Chart of the company's future (projected) P/E BeyondSpring Inc.")
Future (projected) P/E of the market segment - General oncology therapy
BeyondSpring is a biopharmaceutical company developing drugs for the treatment of oncology. Its lead product is aimed at preventing neutropenia, a dangerous side effect of chemotherapy. The chart reflects expectations for the biotech sector, helping to assess the market's perception of this maintenance therapy drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772513436832 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
BeyondSpring is a biopharmaceutical company developing drugs to treat cancer. Their lead candidate is aimed at preventing chemotherapy-induced neutropenia. This chart of overall expectations reflects investor sentiment toward the biotech. Market optimism facilitates raising capital for late-stage clinical trials and commercialization of maintenance therapy for cancer patients.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513436841 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BeyondSpring Inc.
BeyondSpring is a late-stage biopharmaceutical company developing cancer treatments. This chart shows the company's financial position on the threshold of potential commercialization. Future profits depend on regulatory approval for its lead drug, designed to reduce the side effects of chemotherapy.
Profit of companies in the market segment - General oncology therapy
Pyxis Tankers Inc. is a shipping company specializing in the transportation of petroleum products. Its profitability is entirely dependent on tanker freight rates. This chart illustrates the extreme volatility of this shipping segment, where geopolitical events, global fuel consumption, and fleet balance can lead to sharp fluctuations in profitability.
Overall market profit
BeyondSpring is a biotech company whose lead drug is designed to reduce the side effects of chemotherapy. The company's success hinges on regulatory approval and the commercial launch of its product. This is an example of how biotechnology can improve the quality of life for patients undergoing difficult treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BeyondSpring Inc.
BeyondSpring is a biopharmaceutical company developing cancer treatments. Its revenue forecast depends on clinical trial results and regulatory approvals, particularly for its lead drug candidate. This chart reflects analysts' speculative expectations for the future of the company's oncology pipeline.
%20profit%20of%20the%20company%20BeyondSpring%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BeyondSpring-Inc.&v=1772513436965 "Graph of future (projected) profit of the company BeyondSpring Inc.")
Future (predicted) profit of companies in the market segment - General oncology therapy
BeyondSpring is a biopharmaceutical company developing drugs to treat cancer. Its lead candidate is designed to reduce chemotherapy-induced neutropenia and to directly target tumors. This chart shows revenue projections for the oncology sector. It reflects the need for both supportive care and new cancer treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772513436970 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
BeyondSpring Inc. is a biopharmaceutical company developing drugs to treat oncology. The company's success depends on clinical trial results and regulatory approval. This earnings forecast chart is important for assessing market investment appetite, which determines the availability of capital for biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513436983 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BeyondSpring Inc.
BeyondSpring is a biopharmaceutical company developing drugs for the treatment of cancer. Its lead drug candidate is designed to reduce chemotherapy-induced neutropenia. The chart shows investor assessments of the drug's potential, which could become an important part of maintenance therapy for cancer patients.
P/S market segment - General oncology therapy
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company developing innovative oncology therapeutics to address unmet medical needs. This chart shows the average valuation in the sector, providing insight into the market's perception of the revenue potential of BeyondSpring's pipeline.
P/S of the market as a whole
BeyondSpring is a biopharmaceutical company developing drugs to treat oncology. Its lead candidate is aimed at preventing chemotherapy-induced neutropenia. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in supportive cancer therapy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BeyondSpring Inc.
BeyondSpring is a biopharmaceutical company developing cancer treatments. This chart reflects investor expectations for the future success of its lead drug, designed to reduce the side effects of chemotherapy. The valuation is based on potential sales revenue if it receives regulatory approval.
%20P%2FS%20BeyondSpring%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BeyondSpring-Inc.&v=1772513437047 "The graph of the company's future (projected) P/S BeyondSpring Inc.")
Future (projected) P/S of the market segment - General oncology therapy
BeyondSpring Inc. is a biopharmaceutical company developing oncology drugs. Its lead candidate, Plinabulin, is designed to prevent chemotherapy-induced neutropenia. The chart shows investor estimates for BeyondSpring's future sales, reflecting expectations for approval and commercial success of its drugs.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772513437061 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Future revenue expectations in biotech depend on advances in cancer treatment. BeyondSpring, developing drugs to protect the immune system from the effects of chemotherapy and to treat cancer, is working to improve the standard of oncology care. Their clinical successes offer hope for more gentle and effective treatment for millions of patients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513437099 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BeyondSpring Inc.
BeyondSpring is a global clinical-stage biopharmaceutical company developing innovative cancer treatments. Its revenue at this stage is generated not from product sales, but from licensing agreements and partnerships that fund its extensive clinical research program.
Sales of companies in the market segment - General oncology therapy
BeyondSpring Inc. is a biopharmaceutical company whose lead drug, Plinabulin, is designed to reduce neutropenia (a drop in white blood cell count) caused by chemotherapy. This chart shows the overall revenue in the oncology sector. It illustrates the importance of supportive care, which helps patients better tolerate challenging cancer treatments and improves outcomes.
Overall market sales
BeyondSpring is a late-stage biopharmaceutical company developing drugs for the treatment of oncology. Its lead candidate is designed to reduce the side effects of chemotherapy. Success depends on regulatory approval and commercialization. This overall economic situation impacts healthcare budgets, which determine the availability of maintenance therapy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BeyondSpring Inc.
BeyondSpring is a biopharmaceutical company whose lead drug is designed to reduce chemotherapy-induced neutropenia. The company's future depends on regulatory approval and commercial launch. The chart shows analysts' speculative revenue forecasts, which are a bet on the success of its lead drug.
%20sales%20of%20the%20company%20BeyondSpring%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BeyondSpring-Inc.&v=1772513437137 "Schedule of future (projected) sales of the company BeyondSpring Inc.")
Future (projected) sales of companies in the market segment - General oncology therapy
BeyondSpring is a biopharmaceutical company developing drugs for the treatment of cancer. Its lead candidate, plinabulin, is being studied for the prevention of chemotherapy-induced neutropenia and for the treatment of lung cancer. This chart displays projected revenue for the entire oncology sector, providing an overview of overall expectations for the maintenance therapy market in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772513437152 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
BeyondSpring is a late-stage biopharmaceutical company developing drugs for the treatment of oncology. Its lead candidate is designed to reduce the side effects of chemotherapy. Success depends on regulatory approval. This overall economic activity schedule influences the healthcare system, which will decide whether to implement the new drug.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513437164 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BeyondSpring Inc.
BeyondSpring is a biopharmaceutical company developing cancer treatments. This metric reflects its financial progress through the clinical development stage. It demonstrates the level of R&D investment required to bring its lead drug candidate to market and achieve commercial success in oncology.
Market segment marginality - General oncology therapy
BeyondSpring is a clinical-stage biopharmaceutical company developing cancer treatments. Its financial metrics reflect intensive investments in R&D to bring its products to market. This chart provides insight into the company's operating model and cost structure compared to other oncology companies.
Market marginality as a whole
BeyondSpring is a global clinical-stage biopharmaceutical company developing innovative drugs for the treatment of cancer. Their lead candidate is designed to reduce chemotherapy-induced neutropenia. Their future depends on regulatory decisions. This gross margin schedule does not affect their scientific activities but is important for attracting investment.
Employees in the company, segment and market as a whole
Number of employees in the company BeyondSpring Inc.
BeyondSpring is a late-stage biopharmaceutical company developing oncology drugs. This timeline shows how the company is preparing for potential market entry. Growing the team, particularly in the areas of regulatory affairs and commercialization planning, is a key step before submitting for approval of its lead product.
Share of the company's employees BeyondSpring Inc. within the market segment - General oncology therapy
BeyondSpring Inc. is a biopharmaceutical company developing cancer treatments. This chart shows the percentage of oncology clinicians and scientists the company attracts. Its team is working on drugs that not only fight tumors but also protect the immune system from the effects of chemotherapy.
Number of employees in the market segment - General oncology therapy
BeyondSpring Inc. is a biopharmaceutical company developing drugs to treat cancer, specifically chemotherapy-induced neutropenia. This chart shows overall employment in the oncology sector. It illustrates how the company focuses not only on fighting the tumor itself but also on improving patients' quality of life during treatment.
Number of employees in the market as a whole
BeyondSpring Inc. is a biopharmaceutical company whose lead drug is designed to protect against chemotherapy-induced neutropenia and to treat cancer. It is an important supportive therapy. This chart illustrates the labor market, where biotech companies working to improve patients' quality of life are creating jobs for scientists, physicians, and clinical research specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BeyondSpring Inc. (BYSI)
BeyondSpring Inc. is a global biopharmaceutical company developing innovative cancer treatments. This chart is a classic example of biotech. The very high market capitalization per employee means the market is not evaluating current operations, but the enormous potential of the drug being developed by a small but highly qualified team.
%20of%20the%20company%20BeyondSpring%20Inc.%20(BYSI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BeyondSpring-Inc.-BYSI&v=1772513437275 "Chart of market capitalization per employee (in thousands of dollars) of the company BeyondSpring Inc. (BYSI)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
BeyondSpring Inc. is a biopharmaceutical company developing oncology drugs. Their value is determined by the potential of their lead drug candidate. This metric demonstrates the enormous value the market places on the success of this single product. A high valuation reflects investors' hopes that it will become a blockbuster and change the standard of care.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772513437293 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing cancer treatments. Its value is almost entirely dependent on clinical trial results and regulatory approvals. This metric illustrates the high risk and high potential rewards in biotech, where a company's fate can hinge on a single drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513437310 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BeyondSpring Inc. (BYSI)
BeyondSpring (BYSI) is a biotech company with both an approved drug in China and an R&D pipeline. It operates under a hybrid model. This chart shows the net balance between commercial revenue (if any) and R&D costs for bringing drugs to the US market, calculated per employee.
%20Chart%20BeyondSpring%20Inc.%20(BYSI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BeyondSpring-Inc.-BYSI&v=1772513437341 "Company Profit Per Employee (in thousands of dollars) Chart BeyondSpring Inc. (BYSI)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
BeyondSpring is a clinical-stage biopharmaceutical company. Like most biotech companies in the R&D phase, this metric is currently negative. This chart provides a benchmark for the future. Success will depend on whether their scientific team can bring their drug candidates to approval, which will determine their future profitability.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772513437352 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
BeyondSpring (BYSI) is a biopharmaceutical company developing oncology drugs. Their business is R&D. This chart shows a typical biotech scenario: negative profit per employee, as all resources are invested in clinical trials to obtain FDA approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513437373 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BeyondSpring Inc. (BYSI)
This chart for BeyondSpring, a biopharmaceutical company developing cancer treatments, shows progress in commercialization. Revenue per employee growth will depend on the approval and successful launch of its lead drug candidate.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BeyondSpring-Inc.-BYSI&v=1772513437408 "Sales chart per company employee BeyondSpring Inc. (BYSI)")
Sales per employee in the market segment - General oncology therapy
BeyondSpring (BYSI) is a clinical-stage biopharmaceutical company developing oncology drugs, specifically those that protect against chemotherapy. This is R&D. This metric reflects the average revenue per employee in the segment. It allows one to assess how productive their R&D team is compared to other oncology biotechs.
Sales per employee for the market as a whole
BeyondSpring (BYSI) is a clinical-stage biopharmaceutical company developing cancer treatments. Currently, its staff consists primarily of scientists and researchers. This metric is particularly interesting for BYSI: it reflects the transition from pure R&D to commercialization. Until a drug is approved, this value is close to zero.
Short shares by company, segment and market as a whole
Shares shorted by company BeyondSpring Inc. (BYSI)
BeyondSpring is a biotech company whose lead drug (Plinabulin) was rejected by the FDA. Its future now depends on early-stage development. This chart shows how many investors are betting that the company has no valuable assets left and is a shell company slowly burning through its remaining cash.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BeyondSpring-Inc.-BYSI&v=1772513437510 "Short Shares Chart for the Company BeyondSpring Inc. (BYSI)")
Shares shorted by market segment - General oncology therapy
BeyondSpring (BYSI) is a biopharmaceutical company developing drugs to treat cancer, specifically chemotherapy-induced neutropenia. This chart shows the overall short position in the oncology biotech sector, reflecting investor skepticism about its clinical data and the drug's chances of approval.
Shares shorted by the overall market
BeyondSpring (BYSI) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like BYSI in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BeyondSpring Inc. (BYSI)
For BeyondSpring, this oscillator is a barometer of hope for their lead drug, Plinabulin. The company is promoting it for the treatment of chemotherapy side effects (neutropenia) and for lung cancer. "Overbought" levels (above 70) arise in anticipation of an FDA decision. A complete rejection (CRL) from the regulator for the lead indication immediately plunged the oscillator into "oversold" levels (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BeyondSpring-Inc.-BYSI&v=1772513437559 "RSI 14 indicator chart for the company's stock BeyondSpring Inc. (BYSI)")
RSI 14 Market Segment - General oncology therapy
BeyondSpring (BYSI) is a biotech (China/USA) cancer hunter. Their signature product is a drug (Plinabulin) that protects bone marrow from chemotherapy. The "General Oncology Therapy" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is BYSI's growth due to their R&D or is the entire biotech sector "overheated"?
RSI 14 for the overall market
BeyondSpring (BYSI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BYSI (BeyondSpring Inc.)
BeyondSpring is a biopharmaceutical company whose lead drug (Plinabulin) failed in lung cancer trials but is now being studied for other uses. This chart shows the speculative average price target from analysts, reflecting their assessment of the remaining potential of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BYSI-BeyondSpring-Inc.&v=1772513437593 "A chart showing analyst consensus forecasts for the expected stock price. BYSI (BeyondSpring Inc.)")
The difference between the consensus estimate and the actual stock price BYSI (BeyondSpring Inc.)
BeyondSpring (BYSI) is a biotech company (China/USA) whose lead drug (Plinabulin) is being developed to protect against the side effects of chemotherapy. This chart is a barometer of their R&D. It measures the gap between the price (low after the FDA setback) and the consensus target, reflecting whether analysts believe they have a "second chance."
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BYSI-BeyondSpring-Inc.&v=1772513437613 "A chart showing the difference between the consensus forecast and the actual stock price. BYSI (BeyondSpring Inc.)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
BeyondSpring (BYSI) is a biotech company whose main asset (Plinabulin) is being developed to treat chemotherapy side effects (neutropenia) and lung cancer. This chart shows overall expectations for the general oncology sector. It reflects whether experts have confidence in the company's R&D pipeline after past failures.
Analysts' consensus forecast for the overall market share price
BeyondSpring (BYSI) is a biotech company developing drugs to treat cancer (Plinabulin) and protect against the side effects of chemotherapy. This chart shows overall risk appetite. For BYSI, a company with a history of regulatory setbacks, overall market optimism is important for raising capital, but news from the FDA and partners carries far more weight.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BeyondSpring Inc.
BeyondSpring is a biotech company whose fate is tied to the drug Plinabulin. They are trying to bring it to market for two purposes: preventing chemotherapy-associated adverse events (CIN) and treating lung cancer. This chart summarizes their battle with the FDA. It reflects their long and difficult regulatory journey, especially after the FDA rejected their initial application.
AKIMA Market Segment Index - General oncology therapy
BeyondSpring Inc. (BYSI) is a biopharmaceutical company whose flagship drug, Plinabulin, was developed for the treatment of chemotherapy side effects and lung cancer. The chart shows the segment average. It helps investors assess how BeyondSpring's risks and potential, especially after regulatory decisions, compare to the general oncology sector average.
The AKIM Index for the overall market
BeyondSpring is a global biopharmaceutical company developing immuno-oncology therapies. Its key asset is Plinabulin. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which faces regulatory challenges in the US and China, stacks up against the backdrop of overall economic trends.
